Benzinga | Jan 5, 2021 05:11AM EST

BMO Capital Initiates Coverage On AbCellera Biologics with Outperform Rating, Announces Price Target of $48

BMO Capital analyst Do Kim initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Outperform rating and announces Price Target of $48.